Table 1

Patients' baseline demographics and clinical characteristics3

CharacteristicValue (N=106)
Age, years
Race, n (%)
 White102 (96)
 Asian2 (2)
 Not reported2 (2)
Ethnicity, n (%)
 Hispanic or Latino2 (2)
 Not Hispanic or Latino99 (93)
 Not reported4 (4)
 Unknown1 (1)
Primary diagnosis, n (%)
 Epithelial ovarian85 (80)
 Fallopian tube*8 (8)
 Primary peritoneal*12 (11)
 Other†1 (1)
Histology, n (%)
 High-grade serous106 (100)
Stage at initial diagnosis, n (%)
 I2 (2)
 II0 (0)
 III63 (59)
 IV40 (38)
 Missing1 (1)
Eastern Cooperative Oncology Group performance status, n (%)
 060 (57)
 146 (43)
BReast CAncer gene (BRCA) mutations‡
 Yes21 (20)
 BRCA115 (14)
 BRCA26 (6)
 No/unknown85 (80)
Prior systemic therapy, n (%)§
 110 (9)
 241 (39)
 354 (51)
Prior exposure, n (%)
 Platinum-containing regimen106 (100)
 Bevacizumab106 (100)
 Taxanes105 (99)
 Liposomal doxorubicin75 (71)
 Poly (ADP-ribose) polymerase inhibitor (PARPi)51 (48)
 Topotecan0 (0)
Primary platinum-free interval, n (%)¶
 0–12 months63 (59)
 >12 months43 (41)
Platinum-free interval, n (%)**, ††
 0–3 months39 (37)
 3–6 months64 (60)
  • Table used with permission from Matulonis UA et al 3 2023, Wolters Kluwer Health.

  • *The term epithelial ovarian cancer often includes fallopian tube carcinoma and primary peritoneal carcinoma, as they have the same prognosis and treatment.

  • †One patient with primary diagnosis categorized as other had histopathology consistent with the inclusion/exclusion criteria, intraepithelial tubo-ovarian carcinoma.

  • ‡The BReast CAncer gene (BRCA) mutation status from prior testing was recorded from the source record. Patients with a germline or somatic BRCA mutation in the tumor tissue were classified as positive, patients who were tested and had no BRCA mutation were classified as negative, and patients without known BRCA mutation status were classified as unknown. The no and unknown fields were grouped in the database.

  • §One patient had received four prior lines of therapy.

  • ¶Time from last dose of the first-line platinum therapy to the date of disease progression and/or relapse following the first-line therapy.

  • **Time from last dose of the latest-line platinum therapy (most recent line prior to trial entry) to the date of disease progression and/or relapse following that line of therapy.

  • ††Three patients were enrolled with a platinum-free interval of >6 months, of which 2 patients had a platinum-free interval of 6.01 months and 1 patient had a platinum-free interval of 18.07 months.